PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31301418-6	2019	KEY FINDINGS: LLDT-8 treatment significantly inhibited hepatic injury featured by the decrease of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), the lessening of hepatic ballooning and macrovesicular steatosis.	5alpha-Hydroxytriptolide	14-20	glutamic pyruvic transaminase, soluble	Mus musculus	104-128
31301418-6	2019	KEY FINDINGS: LLDT-8 treatment significantly inhibited hepatic injury featured by the decrease of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), the lessening of hepatic ballooning and macrovesicular steatosis.	5alpha-Hydroxytriptolide	14-20	glutamic pyruvic transaminase, soluble	Mus musculus	130-133
31301418-6	2019	KEY FINDINGS: LLDT-8 treatment significantly inhibited hepatic injury featured by the decrease of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), the lessening of hepatic ballooning and macrovesicular steatosis.	5alpha-Hydroxytriptolide	14-20	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	139-161
31301418-6	2019	KEY FINDINGS: LLDT-8 treatment significantly inhibited hepatic injury featured by the decrease of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), the lessening of hepatic ballooning and macrovesicular steatosis.	5alpha-Hydroxytriptolide	14-20	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	163-166
31301418-7	2019	Moreover, LLDT-8 could downregulate the expression of stearoyl-CoA desaturase 1 (SCD1), which further led to the lower ratios of C16:1/C16:0 and C18:1/C18:0 and thus inhibited lipid synthesis.	5alpha-Hydroxytriptolide	10-16	stearoyl-Coenzyme A desaturase 1	Mus musculus	54-79
31301418-7	2019	Moreover, LLDT-8 could downregulate the expression of stearoyl-CoA desaturase 1 (SCD1), which further led to the lower ratios of C16:1/C16:0 and C18:1/C18:0 and thus inhibited lipid synthesis.	5alpha-Hydroxytriptolide	10-16	stearoyl-Coenzyme A desaturase 1	Mus musculus	81-85
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	peroxisome proliferator activated receptor alpha	Mus musculus	45-93
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	peroxisome proliferator activated receptor alpha	Mus musculus	95-104
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	carnitine palmitoyltransferase 1a, liver	Mus musculus	142-147
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	acyl-Coenzyme A oxidase 1, palmitoyl	Mus musculus	162-180
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	acyl-Coenzyme A oxidase 1, palmitoyl	Mus musculus	182-187
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	acyl-Coenzyme A dehydrogenase, long-chain	Mus musculus	225-230
31301418-8	2019	LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.	5alpha-Hydroxytriptolide	0-6	acyl-Coenzyme A dehydrogenase, medium chain	Mus musculus	273-278
25887296-0	2015	(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.	5alpha-Hydroxytriptolide	0-24	TNF superfamily member 11	Homo sapiens	66-71
29283173-4	2018	In vitro studies using recombinant human cytochrome P450 enzyme demonstrated that cytochrome P450 3A4 (CYP3A4) was predominant in the metabolism of triptolide and (5R)-5-hydroxytriptolide, accounting for 94.2% and 64.2% of the metabolism, respectively.	5alpha-Hydroxytriptolide	163-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-101
29283173-4	2018	In vitro studies using recombinant human cytochrome P450 enzyme demonstrated that cytochrome P450 3A4 (CYP3A4) was predominant in the metabolism of triptolide and (5R)-5-hydroxytriptolide, accounting for 94.2% and 64.2% of the metabolism, respectively.	5alpha-Hydroxytriptolide	163-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109
29283173-6	2018	The plasma exposure to triptolide and (5R)-5-hydroxytriptolide in the rats was significantly increased when co-administered with the CYP3a inhibitor ritonavir (30 mg/kg, po) with the values of AUC0-  (area under the plasma concentration-time curve from time zero extrapolated to infinity) being increased by 6.84 and 1.83 times, respectively.	5alpha-Hydroxytriptolide	38-62	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	133-138
29283173-7	2018	When pretreated with the CYP3a inducer dexamethasone (50 mg kg-1 d-1, for 3 d), the AUC0-  values of triptolide and (5R)-5-hydroxytriptolide were decreased by 85.4% and 91.4%, respectively.	5alpha-Hydroxytriptolide	116-140	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	25-30
29283173-8	2018	These results suggest that both triptolide and (5R)-5-hydroxytriptolide are sensitive substrates of CYP3a.	5alpha-Hydroxytriptolide	47-71	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	100-105
28100505-0	2017	(5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/lpr mice by preventing infiltration of immune cells.	5alpha-Hydroxytriptolide	0-24	Fas (TNF receptor superfamily member 6)	Mus musculus	60-63
28100505-2	2017	In this study, we aimed to investigate the therapeutic effects of LLDT-8 on lupus nephritis in MRL/lpr mice, a model of systemic lupus erythematosus.	5alpha-Hydroxytriptolide	66-72	Fas (TNF receptor superfamily member 6)	Mus musculus	99-102
28100505-4	2017	A decreased expression of the inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF-alpha was also observed in the kidney of LLDT-8 treated MRL/lpr mice.	5alpha-Hydroxytriptolide	126-132	interferon gamma	Mus musculus	53-62
28100505-4	2017	A decreased expression of the inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF-alpha was also observed in the kidney of LLDT-8 treated MRL/lpr mice.	5alpha-Hydroxytriptolide	126-132	interleukin 17A	Mus musculus	64-69
28100505-4	2017	A decreased expression of the inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF-alpha was also observed in the kidney of LLDT-8 treated MRL/lpr mice.	5alpha-Hydroxytriptolide	126-132	interleukin 6	Mus musculus	71-75
28100505-4	2017	A decreased expression of the inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF-alpha was also observed in the kidney of LLDT-8 treated MRL/lpr mice.	5alpha-Hydroxytriptolide	126-132	tumor necrosis factor	Mus musculus	81-90
28100505-4	2017	A decreased expression of the inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF-alpha was also observed in the kidney of LLDT-8 treated MRL/lpr mice.	5alpha-Hydroxytriptolide	126-132	Fas (TNF receptor superfamily member 6)	Mus musculus	145-148
28100505-5	2017	Moreover, infiltration of T cells in the kidney was mitigated after LLDT-8 treatment, corresponding with decreased expression of related chemokines IP-10, Mig, and RANTES in the kidney.	5alpha-Hydroxytriptolide	68-74	chemokine (C-X-C motif) ligand 10	Mus musculus	148-153
28100505-5	2017	Moreover, infiltration of T cells in the kidney was mitigated after LLDT-8 treatment, corresponding with decreased expression of related chemokines IP-10, Mig, and RANTES in the kidney.	5alpha-Hydroxytriptolide	68-74	chemokine (C-X-C motif) ligand 9	Mus musculus	155-158
28100505-5	2017	Moreover, infiltration of T cells in the kidney was mitigated after LLDT-8 treatment, corresponding with decreased expression of related chemokines IP-10, Mig, and RANTES in the kidney.	5alpha-Hydroxytriptolide	68-74	chemokine (C-C motif) ligand 5	Mus musculus	164-170
28100505-7	2017	In the human proximal tubule epithelial cell line and mouse mesangial cell line, consistent with our in vivo experimental results, LLDT-8 suppressed the expression of related chemokines and IL-6.	5alpha-Hydroxytriptolide	131-137	interleukin 6	Mus musculus	190-194
28100505-8	2017	In summary, LLDT-8 has a therapeutic benefit for lupus nephritis via suppressing chemokine expression and inhibiting immune cell infiltration in kidneys of MRL/lpr mice.	5alpha-Hydroxytriptolide	12-18	Fas (TNF receptor superfamily member 6)	Mus musculus	160-163
27286958-8	2016	LLDT-8 inhibited NO release and expression of TNF-alpha, IL-1beta and iNOS in BV-2 microglia and primary microglia treated with LPS.	5alpha-Hydroxytriptolide	0-6	tumor necrosis factor	Homo sapiens	46-55
27286958-8	2016	LLDT-8 inhibited NO release and expression of TNF-alpha, IL-1beta and iNOS in BV-2 microglia and primary microglia treated with LPS.	5alpha-Hydroxytriptolide	0-6	interleukin 1 beta	Homo sapiens	57-65
27286958-8	2016	LLDT-8 inhibited NO release and expression of TNF-alpha, IL-1beta and iNOS in BV-2 microglia and primary microglia treated with LPS.	5alpha-Hydroxytriptolide	0-6	inositol-3-phosphate synthase 1	Homo sapiens	70-74
27286958-9	2016	In addition, LLDT-8 suppressed expression of TLR4, degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	5alpha-Hydroxytriptolide	13-19	toll like receptor 4	Homo sapiens	45-49
27286958-9	2016	In addition, LLDT-8 suppressed expression of TLR4, degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	5alpha-Hydroxytriptolide	13-19	NFKB inhibitor alpha	Homo sapiens	66-78
27286958-9	2016	In addition, LLDT-8 suppressed expression of TLR4, degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	5alpha-Hydroxytriptolide	13-19	nuclear factor kappa B subunit 1	Homo sapiens	108-117
27286958-10	2016	CONCLUSION: LLDT-8 exerted anti-inflammatory effects and protected against acute cerebral ischemia/reperfusion injury possibly by acting through the IkappaB/NF-kappaB cascade to suppress microglia-mediated neuroinflammation.	5alpha-Hydroxytriptolide	12-18	nuclear factor kappa B subunit 1	Homo sapiens	157-166
30688278-9	2019	Our data revealed that (5R)-5-hydroxytriptolide inhibited the generation of nitric oxide, tumor necrosis factor-alpha and interleukin-1beta from primary astrocytes activated by lipopolysaccharide, decreased the positive reaction intensity of glial fibrillary acidic protein, reduced the expression of tumor necrosis factor alpha and interleukin-1beta in culture supernatant, inhibited the phosphorylation of IkappaB-alpha and the translocation of nuclear factor-kappaB/P65 to the nucleus.	5alpha-Hydroxytriptolide	23-47	tumor necrosis factor	Rattus norvegicus	90-117
30688278-9	2019	Our data revealed that (5R)-5-hydroxytriptolide inhibited the generation of nitric oxide, tumor necrosis factor-alpha and interleukin-1beta from primary astrocytes activated by lipopolysaccharide, decreased the positive reaction intensity of glial fibrillary acidic protein, reduced the expression of tumor necrosis factor alpha and interleukin-1beta in culture supernatant, inhibited the phosphorylation of IkappaB-alpha and the translocation of nuclear factor-kappaB/P65 to the nucleus.	5alpha-Hydroxytriptolide	23-47	interleukin 1 beta	Rattus norvegicus	122-139
30688278-9	2019	Our data revealed that (5R)-5-hydroxytriptolide inhibited the generation of nitric oxide, tumor necrosis factor-alpha and interleukin-1beta from primary astrocytes activated by lipopolysaccharide, decreased the positive reaction intensity of glial fibrillary acidic protein, reduced the expression of tumor necrosis factor alpha and interleukin-1beta in culture supernatant, inhibited the phosphorylation of IkappaB-alpha and the translocation of nuclear factor-kappaB/P65 to the nucleus.	5alpha-Hydroxytriptolide	23-47	tumor necrosis factor	Rattus norvegicus	301-328
30688278-9	2019	Our data revealed that (5R)-5-hydroxytriptolide inhibited the generation of nitric oxide, tumor necrosis factor-alpha and interleukin-1beta from primary astrocytes activated by lipopolysaccharide, decreased the positive reaction intensity of glial fibrillary acidic protein, reduced the expression of tumor necrosis factor alpha and interleukin-1beta in culture supernatant, inhibited the phosphorylation of IkappaB-alpha and the translocation of nuclear factor-kappaB/P65 to the nucleus.	5alpha-Hydroxytriptolide	23-47	interleukin 1 beta	Rattus norvegicus	333-350
30688278-9	2019	Our data revealed that (5R)-5-hydroxytriptolide inhibited the generation of nitric oxide, tumor necrosis factor-alpha and interleukin-1beta from primary astrocytes activated by lipopolysaccharide, decreased the positive reaction intensity of glial fibrillary acidic protein, reduced the expression of tumor necrosis factor alpha and interleukin-1beta in culture supernatant, inhibited the phosphorylation of IkappaB-alpha and the translocation of nuclear factor-kappaB/P65 to the nucleus.	5alpha-Hydroxytriptolide	23-47	NFKB inhibitor alpha	Rattus norvegicus	408-421
30688278-9	2019	Our data revealed that (5R)-5-hydroxytriptolide inhibited the generation of nitric oxide, tumor necrosis factor-alpha and interleukin-1beta from primary astrocytes activated by lipopolysaccharide, decreased the positive reaction intensity of glial fibrillary acidic protein, reduced the expression of tumor necrosis factor alpha and interleukin-1beta in culture supernatant, inhibited the phosphorylation of IkappaB-alpha and the translocation of nuclear factor-kappaB/P65 to the nucleus.	5alpha-Hydroxytriptolide	23-47	synaptotagmin 1	Rattus norvegicus	469-472
28880016-7	2018	Furthermore, LLDT-8 inhibited inflammation in the kidney evidenced by significantly decreasing C3 and IgG deposition, reducing the levels of the pathogenic cytokines TNF-alpha, IL-6, IL-17, and IFN-gamma, and reducing related chemokine expression and leukocyte infiltration in kidneys.	5alpha-Hydroxytriptolide	13-19	tumor necrosis factor	Mus musculus	166-175
28880016-7	2018	Furthermore, LLDT-8 inhibited inflammation in the kidney evidenced by significantly decreasing C3 and IgG deposition, reducing the levels of the pathogenic cytokines TNF-alpha, IL-6, IL-17, and IFN-gamma, and reducing related chemokine expression and leukocyte infiltration in kidneys.	5alpha-Hydroxytriptolide	13-19	interleukin 6	Mus musculus	177-181
28880016-7	2018	Furthermore, LLDT-8 inhibited inflammation in the kidney evidenced by significantly decreasing C3 and IgG deposition, reducing the levels of the pathogenic cytokines TNF-alpha, IL-6, IL-17, and IFN-gamma, and reducing related chemokine expression and leukocyte infiltration in kidneys.	5alpha-Hydroxytriptolide	13-19	interleukin 17A	Mus musculus	183-188
28880016-7	2018	Furthermore, LLDT-8 inhibited inflammation in the kidney evidenced by significantly decreasing C3 and IgG deposition, reducing the levels of the pathogenic cytokines TNF-alpha, IL-6, IL-17, and IFN-gamma, and reducing related chemokine expression and leukocyte infiltration in kidneys.	5alpha-Hydroxytriptolide	13-19	interferon gamma	Mus musculus	194-203
28880016-8	2018	Moreover, LLDT-8 treatment significantly increased the expression of FcgammaRIIB in the kidney and spleen.	5alpha-Hydroxytriptolide	10-16	Fc receptor, IgG, low affinity IIb	Mus musculus	69-80
29209210-0	2017	Critical Role of Hepatic Cyp450s in the Testis-Specific Toxicity of (5R)-5-Hydroxytriptolide in C57BL/6 Mice.	5alpha-Hydroxytriptolide	68-92	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	25-28
29209210-5	2017	gamma-H2AX, a marker of meiosis process, its localization and protein level in testis showed a distinct meiosis block induced by LLDT-8.	5alpha-Hydroxytriptolide	129-135	H2A.X variant histone	Mus musculus	0-10
27882124-0	2016	(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis.	5alpha-Hydroxytriptolide	0-24	TNF receptor superfamily member 11B	Rattus norvegicus	78-81
27882124-0	2016	(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis.	5alpha-Hydroxytriptolide	0-24	TNF superfamily member 11	Rattus norvegicus	87-92
27882124-0	2016	(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis.	5alpha-Hydroxytriptolide	26-32	TNF receptor superfamily member 11B	Rattus norvegicus	78-81
27882124-0	2016	(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis.	5alpha-Hydroxytriptolide	26-32	TNF superfamily member 11	Rattus norvegicus	87-92
27882124-9	2016	Furthermore, LLDT-8 administration inhibited collagen-induced inflammation and iNOS protein expression in arthritic rats.	5alpha-Hydroxytriptolide	13-19	nitric oxide synthase 2	Rattus norvegicus	79-83
27882124-10	2016	The current data indicated that MMP-13 production was suppressed and OPG/RANKL expression was increased by LLDT-8 treatment in the arthritic rat.	5alpha-Hydroxytriptolide	107-113	TNF receptor superfamily member 11B	Rattus norvegicus	69-72
27882124-10	2016	The current data indicated that MMP-13 production was suppressed and OPG/RANKL expression was increased by LLDT-8 treatment in the arthritic rat.	5alpha-Hydroxytriptolide	107-113	TNF superfamily member 11	Rattus norvegicus	73-78
27882124-11	2016	The present results suggest that LLDT-8 attenuates CIA through OPG/RANK/RANK ligand signaling in a rat model of RA.	5alpha-Hydroxytriptolide	33-39	TNF receptor superfamily member 11B	Rattus norvegicus	63-66
30090373-0	2016	Dephosphorylation of Tak1 at Ser412 greatly contributes to the spermatocyte-specific testis toxicity induced by (5R)-5-hydroxytriptolide in C57BL/6 mice.	5alpha-Hydroxytriptolide	112-136	mitogen-activated protein kinase kinase kinase 7	Mus musculus	21-25
30090373-6	2016	MAPK activity screening identified that TGF-beta activated kinase 1 (Tak1) is critical in LLDT-8 induced apoptosis.	5alpha-Hydroxytriptolide	90-96	mitogen-activated protein kinase kinase kinase 7	Mus musculus	40-67
30090373-6	2016	MAPK activity screening identified that TGF-beta activated kinase 1 (Tak1) is critical in LLDT-8 induced apoptosis.	5alpha-Hydroxytriptolide	90-96	mitogen-activated protein kinase kinase kinase 7	Mus musculus	69-73
30090373-7	2016	LLDT-8 reduced the Tak1 protein and dephosphorylated Tak1 at Ser412 in GC-2spd and the testes, but not in TM4.	5alpha-Hydroxytriptolide	0-6	mitogen-activated protein kinase kinase kinase 7	Mus musculus	19-23
30090373-7	2016	LLDT-8 reduced the Tak1 protein and dephosphorylated Tak1 at Ser412 in GC-2spd and the testes, but not in TM4.	5alpha-Hydroxytriptolide	0-6	mitogen-activated protein kinase kinase kinase 7	Mus musculus	53-57
30090373-9	2016	Meanwhile, activating Tak1 rescued up to 50% of the GC-2spd cells from the apoptosis induced by LLDT-8.	5alpha-Hydroxytriptolide	96-102	mitogen-activated protein kinase kinase kinase 7	Mus musculus	22-26
30090373-10	2016	Altogether, our study firstly revealed the important role of Tak1 in the survival of spermatocytes, and dephosphorylation of Tak1 at Ser412 may contribute to the spermatocyte-specific testis toxicity induced by LLDT-8.	5alpha-Hydroxytriptolide	211-217	mitogen-activated protein kinase kinase kinase 7	Mus musculus	125-129
25887296-0	2015	(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.	5alpha-Hydroxytriptolide	0-24	TNF receptor superfamily member 11b	Homo sapiens	77-80
25887296-0	2015	(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.	5alpha-Hydroxytriptolide	26-32	TNF superfamily member 11	Homo sapiens	66-71
25887296-0	2015	(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.	5alpha-Hydroxytriptolide	26-32	TNF receptor superfamily member 11b	Homo sapiens	77-80
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	80-104	TNF receptor superfamily member 11a	Homo sapiens	117-161
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	80-104	TNF superfamily member 11	Homo sapiens	170-175
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	80-104	TNF receptor superfamily member 11a	Homo sapiens	177-221
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	80-104	TNF receptor superfamily member 11b	Homo sapiens	229-244
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	80-104	TNF receptor superfamily member 11b	Homo sapiens	246-249
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	106-112	TNF receptor superfamily member 11a	Homo sapiens	117-161
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	106-112	TNF superfamily member 11	Homo sapiens	170-175
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	106-112	TNF receptor superfamily member 11a	Homo sapiens	177-221
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	106-112	TNF receptor superfamily member 11b	Homo sapiens	229-244
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	106-112	TNF receptor superfamily member 11b	Homo sapiens	246-249
25887296-6	2015	RESULTS: LLDT-8 increased the rate of OPG expression in CD3(+) T leukomonocytes in peripheral blood as well as the ratio of OPG/RANKL in both peripheral blood and synovial fluid.	5alpha-Hydroxytriptolide	9-15	TNF receptor superfamily member 11b	Homo sapiens	38-41
25887296-8	2015	In addition, LLDT-8 decreased the number of TRAP-positive cells derived from RAW264.7 in the presence of RANKL and M-CSF.	5alpha-Hydroxytriptolide	13-19	TNF superfamily member 11	Homo sapiens	105-110
25887296-8	2015	In addition, LLDT-8 decreased the number of TRAP-positive cells derived from RAW264.7 in the presence of RANKL and M-CSF.	5alpha-Hydroxytriptolide	13-19	colony stimulating factor 1	Homo sapiens	115-120
25887296-9	2015	Furthermore, LLDT-8 also inhibited the expression of p-IkappaB, a key regulator of RANKL signaling pathway.	5alpha-Hydroxytriptolide	13-19	TNF superfamily member 11	Homo sapiens	83-88
25887296-10	2015	CONCLUSIONS: LLDT-8 exerts its anti-osteoclastogenesis effect in RA probably through regulating RANKL/RANK/OPG system and its downstream signaling pathway as well as cytokine productions.	5alpha-Hydroxytriptolide	13-19	TNF superfamily member 11	Homo sapiens	96-101
25887296-10	2015	CONCLUSIONS: LLDT-8 exerts its anti-osteoclastogenesis effect in RA probably through regulating RANKL/RANK/OPG system and its downstream signaling pathway as well as cytokine productions.	5alpha-Hydroxytriptolide	13-19	TNF receptor superfamily member 11b	Homo sapiens	107-110
17112417-0	2006	(5R)-5-hydroxytriptolide inhibits IFN-gamma-related signaling.	5alpha-Hydroxytriptolide	0-24	interferon gamma	Mus musculus	34-43
18952005-12	2009	However, LLDT-8 significantly reduced IFN-gamma-expressing T cell percentages and IFN-gamma mRNA transcription in PHA-activated T cells.	5alpha-Hydroxytriptolide	9-15	interferon gamma	Homo sapiens	38-47
18952005-12	2009	However, LLDT-8 significantly reduced IFN-gamma-expressing T cell percentages and IFN-gamma mRNA transcription in PHA-activated T cells.	5alpha-Hydroxytriptolide	9-15	interferon gamma	Homo sapiens	82-91
17376291-6	2007	Moreover, LLDT-8 suppressed TNF-alpha, IL-4, and TGF-beta production in the lung homogenates.	5alpha-Hydroxytriptolide	10-16	tumor necrosis factor	Mus musculus	28-37
17376291-6	2007	Moreover, LLDT-8 suppressed TNF-alpha, IL-4, and TGF-beta production in the lung homogenates.	5alpha-Hydroxytriptolide	10-16	interleukin 4	Mus musculus	39-43
17376291-6	2007	Moreover, LLDT-8 suppressed TNF-alpha, IL-4, and TGF-beta production in the lung homogenates.	5alpha-Hydroxytriptolide	10-16	transforming growth factor, beta 1	Mus musculus	49-57
17112417-2	2006	Here, we aim to further clarify the effect of LLDT-8 on the pro-inflammatory cytokine IFN-gamma.	5alpha-Hydroxytriptolide	46-52	interferon gamma	Mus musculus	86-95
17112417-12	2006	LLDT-8 markedly blocked the cell division of CD4 and CD8 T cells after ConA stimulation.	5alpha-Hydroxytriptolide	0-6	CD4 antigen	Mus musculus	45-48
17112417-13	2006	LLDT-8 inhibited T cell-derived IFN-gamma production.	5alpha-Hydroxytriptolide	0-6	interferon gamma	Mus musculus	32-41
17112417-14	2006	Moreover, LLDT-8 suppressed the ovalbumin-specific T cell proliferation and IFN-gamma generation.	5alpha-Hydroxytriptolide	10-16	interferon gamma	Mus musculus	76-85
17112417-15	2006	In anti-CD3-activated T cells, LLDT-8 abrogated the mRNA expression of signal transducer and activator of transcription1 (STAT1), T-box transcription factor, IL-12 receptor beta2, STAT4, and interferon regulatory factor 1 in the IFN-gamma expression pathway.	5alpha-Hydroxytriptolide	31-37	CD3 antigen, epsilon polypeptide	Mus musculus	8-11
17112417-15	2006	In anti-CD3-activated T cells, LLDT-8 abrogated the mRNA expression of signal transducer and activator of transcription1 (STAT1), T-box transcription factor, IL-12 receptor beta2, STAT4, and interferon regulatory factor 1 in the IFN-gamma expression pathway.	5alpha-Hydroxytriptolide	31-37	signal transducer and activator of transcription 1	Mus musculus	71-120
17112417-15	2006	In anti-CD3-activated T cells, LLDT-8 abrogated the mRNA expression of signal transducer and activator of transcription1 (STAT1), T-box transcription factor, IL-12 receptor beta2, STAT4, and interferon regulatory factor 1 in the IFN-gamma expression pathway.	5alpha-Hydroxytriptolide	31-37	signal transducer and activator of transcription 1	Mus musculus	122-127
17112417-15	2006	In anti-CD3-activated T cells, LLDT-8 abrogated the mRNA expression of signal transducer and activator of transcription1 (STAT1), T-box transcription factor, IL-12 receptor beta2, STAT4, and interferon regulatory factor 1 in the IFN-gamma expression pathway.	5alpha-Hydroxytriptolide	31-37	signal transducer and activator of transcription 4	Mus musculus	180-185
17112417-15	2006	In anti-CD3-activated T cells, LLDT-8 abrogated the mRNA expression of signal transducer and activator of transcription1 (STAT1), T-box transcription factor, IL-12 receptor beta2, STAT4, and interferon regulatory factor 1 in the IFN-gamma expression pathway.	5alpha-Hydroxytriptolide	31-37	interferon regulatory factor 1	Mus musculus	191-221
17112417-15	2006	In anti-CD3-activated T cells, LLDT-8 abrogated the mRNA expression of signal transducer and activator of transcription1 (STAT1), T-box transcription factor, IL-12 receptor beta2, STAT4, and interferon regulatory factor 1 in the IFN-gamma expression pathway.	5alpha-Hydroxytriptolide	31-37	interferon gamma	Mus musculus	229-238
17112417-16	2006	Western blot analysis showed that LLDT-8 blocked the phosphorylation levels of extracellular signal-regulated kinase, stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase in anti-CD3 plus anti-CD28-activated T cells.	5alpha-Hydroxytriptolide	34-40	mitogen-activated protein kinase 14	Mus musculus	186-189
17112417-16	2006	Western blot analysis showed that LLDT-8 blocked the phosphorylation levels of extracellular signal-regulated kinase, stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase in anti-CD3 plus anti-CD28-activated T cells.	5alpha-Hydroxytriptolide	34-40	CD3 antigen, epsilon polypeptide	Mus musculus	231-234
17112417-18	2006	CONCLUSION: LLDT-8 was a potential inhibitor for IFN-gamma-associated signaling.	5alpha-Hydroxytriptolide	12-18	interferon gamma	Mus musculus	49-58
16712960-4	2006	In vitro, LLDT-8 inhibited primary T cells proliferation, division, IL-2 and IFN-gamma production stimulated with anti-CD3/28.	5alpha-Hydroxytriptolide	10-16	interleukin 2	Homo sapiens	68-72
16574782-0	2006	(5R)-5-hydroxytriptolide attenuated collagen-induced arthritis in DBA/1 mice via suppressing interferon-gamma production and its related signaling.	5alpha-Hydroxytriptolide	0-24	interferon gamma	Mus musculus	93-109
16574782-9	2006	In conclusion, our data suggest that the antiarthritic effect of LLDT-8 is closely related to the blockade of IFN-gamma signaling.	5alpha-Hydroxytriptolide	65-71	interferon gamma	Mus musculus	110-119
16712960-4	2006	In vitro, LLDT-8 inhibited primary T cells proliferation, division, IL-2 and IFN-gamma production stimulated with anti-CD3/28.	5alpha-Hydroxytriptolide	10-16	interferon gamma	Homo sapiens	77-86
16570019-15	2006	LLDT-8 decreased CC chemokine receptor 5 (CCR5) and their ligands macrophage inflammatory protein 1 alpha (MIP-1alpha) and beta (MIP-1beta) mRNA expressions in allografts.	5alpha-Hydroxytriptolide	0-6	chemokine (C-C motif) receptor 5	Mus musculus	17-40
16603150-5	2006	In LLDT-8-treated mice, serum ALT level and histological damage were markedly attenuated.	5alpha-Hydroxytriptolide	3-9	glutamic pyruvic transaminase, soluble	Mus musculus	30-33
16603150-7	2006	These results suggested the therapeutic potential of LLDT-8 in IFN-gamma/STAT1/IRF-1 signaling- and inflammatory cytokines-mediated immune disorders.	5alpha-Hydroxytriptolide	53-59	interferon gamma	Mus musculus	63-72
16603150-7	2006	These results suggested the therapeutic potential of LLDT-8 in IFN-gamma/STAT1/IRF-1 signaling- and inflammatory cytokines-mediated immune disorders.	5alpha-Hydroxytriptolide	53-59	signal transducer and activator of transcription 1	Mus musculus	73-78
16603150-7	2006	These results suggested the therapeutic potential of LLDT-8 in IFN-gamma/STAT1/IRF-1 signaling- and inflammatory cytokines-mediated immune disorders.	5alpha-Hydroxytriptolide	53-59	interferon regulatory factor 1	Mus musculus	79-84
16570019-15	2006	LLDT-8 decreased CC chemokine receptor 5 (CCR5) and their ligands macrophage inflammatory protein 1 alpha (MIP-1alpha) and beta (MIP-1beta) mRNA expressions in allografts.	5alpha-Hydroxytriptolide	0-6	chemokine (C-C motif) receptor 5	Mus musculus	42-46
16570019-15	2006	LLDT-8 decreased CC chemokine receptor 5 (CCR5) and their ligands macrophage inflammatory protein 1 alpha (MIP-1alpha) and beta (MIP-1beta) mRNA expressions in allografts.	5alpha-Hydroxytriptolide	0-6	chemokine (C-C motif) ligand 3	Mus musculus	66-105
16570019-15	2006	LLDT-8 decreased CC chemokine receptor 5 (CCR5) and their ligands macrophage inflammatory protein 1 alpha (MIP-1alpha) and beta (MIP-1beta) mRNA expressions in allografts.	5alpha-Hydroxytriptolide	0-6	chemokine (C-C motif) ligand 3	Mus musculus	107-127
16570019-15	2006	LLDT-8 decreased CC chemokine receptor 5 (CCR5) and their ligands macrophage inflammatory protein 1 alpha (MIP-1alpha) and beta (MIP-1beta) mRNA expressions in allografts.	5alpha-Hydroxytriptolide	0-6	chemokine (C-C motif) ligand 4	Mus musculus	129-138
16166270-5	2006	To further elucidate the mechanism responsible for the inhibition of NO, we examined the effect of LLDT-8 on IFN-gamma and LPS-induced iNOS expression.	5alpha-Hydroxytriptolide	99-105	nitric oxide synthase 2, inducible	Mus musculus	135-139
16166270-6	2006	Indeed, LLDT-8 prevented NO generation by inhibiting iNOS expression at mRNA level and protein level, rather than by interfering its enzymatic activity.	5alpha-Hydroxytriptolide	8-14	nitric oxide synthase 2, inducible	Mus musculus	53-57
16166270-0	2006	Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopolysaccharide-stimulated macrophages.	5alpha-Hydroxytriptolide	60-84	nitric oxide synthase 2, inducible	Mus musculus	14-45
16166270-9	2006	Taken together, these results suggest that LLDT-8 reduces NO production and iNOS expression by inhibiting IFN-gamma-triggered IRF-1 expression and LPS-triggered MAPK phosphorylation and NF-kappaB activation.	5alpha-Hydroxytriptolide	43-49	nitric oxide synthase 2, inducible	Mus musculus	76-80
16166270-0	2006	Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopolysaccharide-stimulated macrophages.	5alpha-Hydroxytriptolide	60-84	interferon gamma	Mus musculus	88-104
16166270-9	2006	Taken together, these results suggest that LLDT-8 reduces NO production and iNOS expression by inhibiting IFN-gamma-triggered IRF-1 expression and LPS-triggered MAPK phosphorylation and NF-kappaB activation.	5alpha-Hydroxytriptolide	43-49	interferon gamma	Mus musculus	106-115
16166270-2	2006	In the present study, we report that LLDT-8 inhibited nitric oxide (NO) production and inducible nitric-oxide synthase (iNOS) expression in macrophages.	5alpha-Hydroxytriptolide	37-43	nitric oxide synthase 2, inducible	Mus musculus	87-118
16166270-9	2006	Taken together, these results suggest that LLDT-8 reduces NO production and iNOS expression by inhibiting IFN-gamma-triggered IRF-1 expression and LPS-triggered MAPK phosphorylation and NF-kappaB activation.	5alpha-Hydroxytriptolide	43-49	interferon regulatory factor 1	Mus musculus	126-131
16166270-2	2006	In the present study, we report that LLDT-8 inhibited nitric oxide (NO) production and inducible nitric-oxide synthase (iNOS) expression in macrophages.	5alpha-Hydroxytriptolide	37-43	nitric oxide synthase 2, inducible	Mus musculus	120-124
16166270-3	2006	LLDT-8 significantly attenuated NO production, in a dose-dependent manner, in primary peritoneal macrophages and a macrophage cell line of Raw 264.7 cells following stimulation with interferon (IFN)-gamma, lipopolysaccharide (LPS), and IFN-gamma plus LPS.	5alpha-Hydroxytriptolide	0-6	interferon gamma	Mus musculus	182-204
16166270-9	2006	Taken together, these results suggest that LLDT-8 reduces NO production and iNOS expression by inhibiting IFN-gamma-triggered IRF-1 expression and LPS-triggered MAPK phosphorylation and NF-kappaB activation.	5alpha-Hydroxytriptolide	43-49	mitogen-activated protein kinase 1	Mus musculus	161-165
16166270-5	2006	To further elucidate the mechanism responsible for the inhibition of NO, we examined the effect of LLDT-8 on IFN-gamma and LPS-induced iNOS expression.	5alpha-Hydroxytriptolide	99-105	interferon gamma	Mus musculus	109-118
16275624-5	2005	LLDT-8 (25, 50, 100 nM) dose-dependently reduced the production of Th1 type cytokines (IFN-gamma, IL-2) and inflammatory cytokines (TNF-alpha, IL-6) in vitro.	5alpha-Hydroxytriptolide	0-6	negative elongation factor complex member C/D, Th1l	Mus musculus	67-70
16275624-5	2005	LLDT-8 (25, 50, 100 nM) dose-dependently reduced the production of Th1 type cytokines (IFN-gamma, IL-2) and inflammatory cytokines (TNF-alpha, IL-6) in vitro.	5alpha-Hydroxytriptolide	0-6	interferon gamma	Mus musculus	87-96
16275624-5	2005	LLDT-8 (25, 50, 100 nM) dose-dependently reduced the production of Th1 type cytokines (IFN-gamma, IL-2) and inflammatory cytokines (TNF-alpha, IL-6) in vitro.	5alpha-Hydroxytriptolide	0-6	interleukin 2	Mus musculus	98-102
16275624-5	2005	LLDT-8 (25, 50, 100 nM) dose-dependently reduced the production of Th1 type cytokines (IFN-gamma, IL-2) and inflammatory cytokines (TNF-alpha, IL-6) in vitro.	5alpha-Hydroxytriptolide	0-6	tumor necrosis factor	Mus musculus	132-141
16275624-5	2005	LLDT-8 (25, 50, 100 nM) dose-dependently reduced the production of Th1 type cytokines (IFN-gamma, IL-2) and inflammatory cytokines (TNF-alpha, IL-6) in vitro.	5alpha-Hydroxytriptolide	0-6	interleukin 6	Mus musculus	143-147
16275625-5	2005	Following days 7 to 28 after allo-BMT, the allogeneic graft survived by increasing the number of engrafted cells (H-2d) in spleens of recipient mice with LLDT-8 treatment.	5alpha-Hydroxytriptolide	154-160	histocompatibility 2, D region	Mus musculus	114-118
16275625-7	2005	Further studies indicated LLDT-8 had a normalizing effect on the ratio of CD4+/CD8+ T cells, and increased CD4+CD25+ T regulatory cells with the Foxp3 expression in splenocytes from LLDT-8 treated mice.	5alpha-Hydroxytriptolide	182-188	forkhead box P3	Mus musculus	145-150
33664742-0	2021	Therapeutic Effects of (5R)-5-Hydroxytriptolide on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via lncRNA WAKMAR2/miR-4478/E2F1/p53 Axis.	5alpha-Hydroxytriptolide	23-47	microRNA 4478	Homo sapiens	123-131
33664742-0	2021	Therapeutic Effects of (5R)-5-Hydroxytriptolide on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via lncRNA WAKMAR2/miR-4478/E2F1/p53 Axis.	5alpha-Hydroxytriptolide	23-47	E2F transcription factor 1	Homo sapiens	132-136
33664742-0	2021	Therapeutic Effects of (5R)-5-Hydroxytriptolide on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via lncRNA WAKMAR2/miR-4478/E2F1/p53 Axis.	5alpha-Hydroxytriptolide	23-47	tumor protein p53	Homo sapiens	137-140
34865994-13	2022	Additionally, LLDT-8-treated BMDCs manifested reduced expression of TLR4, phosphorylation of IkappaBalpha and nuclear translocation of NF-kappaB.	5alpha-Hydroxytriptolide	14-20	toll-like receptor 4	Mus musculus	68-72
34865994-13	2022	Additionally, LLDT-8-treated BMDCs manifested reduced expression of TLR4, phosphorylation of IkappaBalpha and nuclear translocation of NF-kappaB.	5alpha-Hydroxytriptolide	14-20	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	93-105
34865994-13	2022	Additionally, LLDT-8-treated BMDCs manifested reduced expression of TLR4, phosphorylation of IkappaBalpha and nuclear translocation of NF-kappaB.	5alpha-Hydroxytriptolide	14-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	135-144
34865994-16	2022	In conclusion, LLDT-8 played a protective role against ALI and suppressed dendritic cell activation potentially through affecting TLR4 expression and NF-kappaB signaling.	5alpha-Hydroxytriptolide	15-21	toll like receptor 4	Homo sapiens	130-134
34865994-16	2022	In conclusion, LLDT-8 played a protective role against ALI and suppressed dendritic cell activation potentially through affecting TLR4 expression and NF-kappaB signaling.	5alpha-Hydroxytriptolide	15-21	nuclear factor kappa B subunit 1	Homo sapiens	150-159
34015449-0	2021	Triptolide analogue LLDT-8 ameliorates psoriasis-like dermatitis in BALB/c mice via suppressing the IL-36alpha signaling pathway.	5alpha-Hydroxytriptolide	20-26	interleukin 36A	Mus musculus	100-110
34015449-4	2021	Here, we showed that LLDT-8 significantly attenuated symptoms of psoriasis-like dermatitis induced by imiquimod (IMQ, a TLR7 agonist) by reducing the Psoriasis Area and Severity Index (PASI) score and inflammatory parameters.	5alpha-Hydroxytriptolide	21-27	toll-like receptor 7	Mus musculus	120-124
34015449-5	2021	The action of LLDT-8 was involved in down-regulated interleukin (IL)-36alpha expression and blocked IL-36alpha pathway by LC-MS-based label-free quantitative (LFQ) proteomic approach and further experiments.	5alpha-Hydroxytriptolide	14-20	interleukin 36A	Mus musculus	52-76
34015449-5	2021	The action of LLDT-8 was involved in down-regulated interleukin (IL)-36alpha expression and blocked IL-36alpha pathway by LC-MS-based label-free quantitative (LFQ) proteomic approach and further experiments.	5alpha-Hydroxytriptolide	14-20	interleukin 36A	Mus musculus	100-110
34015449-6	2021	Meanwhile, we observed that LLDT-8 significantly inhibited the expression of IL-36alpha in R837-treated bone marrow-derived dendritic cells (BMDCs).	5alpha-Hydroxytriptolide	28-34	interleukin 36A	Mus musculus	77-87
34015449-7	2021	In conclusion, LLDT-8 notably alleviated IMQ-induced psoriasis-like skin inflammation via suppressing the IL-36alpha signaling pathway, suggesting LLDT-8 might be a potential drug for the treatment of psoriasis.	5alpha-Hydroxytriptolide	15-21	interleukin 36A	Mus musculus	106-116
34015449-7	2021	In conclusion, LLDT-8 notably alleviated IMQ-induced psoriasis-like skin inflammation via suppressing the IL-36alpha signaling pathway, suggesting LLDT-8 might be a potential drug for the treatment of psoriasis.	5alpha-Hydroxytriptolide	147-153	interleukin 36A	Mus musculus	106-116